COVID-19 trials registries data warehouse

http://en.irct.ir/trial/46826

Masoud Mirzaei

mmirzaei@ssu.ac.ir

2020-09-19

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Ages 18 to 60 years Diagnosis of Covid-19 over the past 24 hours Female patients are not exposed to pregnancy and do not become pregnant until thirty days later. Not taking levamisole for the past five days (due to 16-hour drug half-life) Patients suspected to covid-19 based on clinical signs and symptoms of CT scan and candidate for outpatient treatment No medication other than protocol No underlying disease

Hospitalized Patients Patients with hemodynamic instability History of cirrhosis, hepatitis and severe liver disease, severe renal failure (less than 30ml / min) Patients currently taking levamisole for other uses such as parasitic infection Patients with a history of allergic reaction or sensitivity to levamisole Patients receiving chemotherapy for cancer Pregnancy and lactation Ages less than 18 years and over 60 years Patients with underlying diseases including diabetes and hypertension

2

Yazd University of Medical Sciences

18

60

Iran

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

50

clinical symptoms include fever, cough, shortness of breath Patients need to be hospitalized

Phase 2

[{"arm_notes": "", "treatment_id": 729, "treatment_name": "Levamisole", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]